Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 7/20 | 0.39 |
| ▸ | ABL1 | P00519 | 13/20 | 0.37 |
| ▸ | BCR | P11274 | 12/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4479455 | 0.87 | ABL1 (0.46) | BRAFABL1BCR | |
| SCHEMBL4482633 | 0.87 | ABL1 (0.49) | BRAFABL1BCR | |
| SCHEMBL4471194 | 0.87 | BRAF (0.46) | BRAFABL1BCR | |
| SCHEMBL4478013 | 0.82 | BRAF (0.40) | BRAF | |
| SCHEMBL4476761 | 0.82 | BRAF (0.40) | BRAF | |
| SCHEMBL4469131 | 0.81 | BRAF (0.46) | BRAFABL1BCR | |
| SCHEMBL4462636 | 0.81 | BRAF (0.37) | BRAF | |
| SCHEMBL4465326 | 0.80 | P4HTM (0.41) | BRAF | |
| SCHEMBL1378543 | 0.80 | ABL1 (0.47) | BRAFABL1BCR | |
| SCHEMBL1378235 | 0.80 | ABL1 (0.45) | BRAFABL1BCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7511042-B2 | 1-[5-(5-tert-Butyl-2-methoxy-3-methylsulfamoyl-phenylcarbamoyl)-2-methyl-phenyl]-1H-1,2,3-triazole-4-carboxylic acid (2,2-dimethyl-propyl)-amide; small molecule cytokine inhibitor; optimized efficacy, pharmacokinetic; antiinflammatory agent, osteoarthritis, asthma, gastrointestinal, respiratory disorder | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-20050153972-A1 | 1-[5-(5-tert-Butyl-2-methoxy-3-methylsulfamoyl-phenylcarbamoyl)-2-methyl-phenyl]-1H-1,2,3-triazole-4-carboxylic acid (2,2-dimethyl-propyl)-amide; small molecule cytokine inhibitor; optimized efficacy, pharmacokinetic; antiinflammatory agent, osteoarthritis, asthma, gastrointestinal, respiratory disorder | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153972-A1 | 1-[5-(5-tert-Butyl-2-methoxy-3-methylsulfamoyl-phenylcarbamoyl)-2-methyl-phenyl]-1H-1,2,3-triazole-4-carboxylic acid (2,2-dimethyl-propyl)-amide; small molecule cytokine inhibitor; optimized efficacy, pharmacokinetic; antiinflammatory agent, osteoarthritis, asthma, gastrointestinal, respiratory disorder | IL1A, IL1R1, IL1RN | BRAF 3675/4885ABL1 2932/4885BCR 2114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.